Navigation Links
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
Date:2/17/2009

ticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin and Triapine(R). The Company has filed an NDA with the FDA for Onrigin for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection (formerly Cloretazine (VNP40101M)), delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible rejection by the FDA of our NDA filing, possible rejection by the FDA of our request for priority review, and possible delays in the FDA' s review process beyond our expectation for approval in the second half of 2009, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
5. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
6. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
7. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
8. Tigris Pharmaceuticals Files IND Application for GGTI-2418
9. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
10. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
11. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015  Custom Computer Specialists, Inc. ("Custom"), a leading ... silver sponsors of the Primary Care Development Corporation,s ("PCDC") ... lending their support of PCDC,s mission to expand access ... its founding in 1993, PCDC has been a key ... has financed over 100 completed primary care projects, valued ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  The Dr. ... is now offering a full suite of new ... who,ve had a biopsy, for diagnosing prostate cancer. ... a range of genetic tests for assessing the risk and ... "We,re very excited to now offer these ...
(Date:6/30/2015)... WATERLOO, ONTARIO (PRWEB) , ... June 30, 2015 ... ... case studies prior to launching SmartArch — a revolutionary new archwire that allows ... will provide further clinical evidence of the efficacy of SmartArch. “We’re thrilled about ...
(Date:6/29/2015)... (PRWEB) , ... June 30, 2015 , ... This cutting ... Perkin Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the world’s first ... is in spec deep into the NIR range. Previous spectrophotometer calibration standards, such as ...
Breaking Biology Technology:Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... 29 A Chicago fertility solutions agency,believes it has ... cope with the effects of a free-falling economy: If ... surrogate, are not on public,aid, but don,t have health ... Reproductive Resources (ARR) matches infertile intended,parents with both egg ...
... October 29 Avantium announced today the,successful ... financing round. Avantium,is active in the development ... and bioplastic, and the improvement of,pharmaceutical products. ... its two,proprietary development programs. The focus of ...
... QUEBEC, Oct. 29 The Fondation du Centre ... that Waters,Corporation has donated a Waters(R) Synapt(TM) MS ... -- worth a total C$1.1 million,-- is the ... which is critical,to the creation of the Centre ...
Cached Biology Technology:Fertility Agency Sweetens Incentives to Gestational Surrogates; Finds Interest Up 2Avantium Completes EUR 18 Million Financing Round 2Avantium Completes EUR 18 Million Financing Round 3Avantium Completes EUR 18 Million Financing Round 4Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 2Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 3Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 4Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 5
(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... 2015  With the increasing number and severity of ... concern. The recent compromise of Federal employee data ... authentication within government agencies. HYPR Corp. announced ... (OTP) authenticator, has been submitted for testing and approval ... validation for tamper proofing. The proliferation ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Nations has designated 2011 the "International Year of Chemistry ... contributions to the world around us. This worldwide initiative ... Nations Educational, Scientific and Cultural Organization (UNESCO) and the ... features activities conducted by countries, such as the United ...
... LOUIS, JANUARY 12, 2011: The 17th annual Academy ... from the St. Louis region, will be held at ... The academy,s Peter H. Raven Lifetime Award recognizes ... or technology. The 2011 prize goes to Marcus E. ...
... in the introduction of non-native fresh water species in Galicia ... rest of the Iberian Peninsula. The results show that 31 ... entire Iberian Peninsula have become established in the region over ... non-native species in Galicia and the Iberian Peninsula carried out ...
Cached Biology News:US launches International Year of Chemistry Feb. 1 with panel of world-renowned chemists 2Academy of Science-St. Louis announces recipients of Outstanding St. Louis Scientist Awards 2Academy of Science-St. Louis announces recipients of Outstanding St. Louis Scientist Awards 3Academy of Science-St. Louis announces recipients of Outstanding St. Louis Scientist Awards 4Academy of Science-St. Louis announces recipients of Outstanding St. Louis Scientist Awards 5Academy of Science-St. Louis announces recipients of Outstanding St. Louis Scientist Awards 6More than 31 freshwater species have 'moved' to Galicia over past century 2
... EKMax™ is a recombinant preparation of ... EKMax™ Enterokinase is expressed and isolated from ... highly purified enzyme preparation (2). It recognizes ... bond after the lysine residue. The enzyme ...
Topoisomerase I...
...
... DNA Modification Kit contains reagents required to ... sample. In the bisulfite reaction, all unmethylated ... to uracils, while 5-methylcytosines remain unaltered. Thus, ... differ depending on whether the DNA is ...
Biology Products: